NasdaqGM:FLGT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. More Details


Snowflake Analysis

Exceptional growth potential with flawless balance sheet.


Similar Companies

Share Price & News

How has Fulgent Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FLGT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.3%

FLGT

1.3%

US Healthcare

1.3%

US Market


1 Year Return

273.3%

FLGT

21.2%

US Healthcare

15.8%

US Market

Return vs Industry: FLGT exceeded the US Healthcare industry which returned 21% over the past year.

Return vs Market: FLGT exceeded the US Market which returned 13.8% over the past year.


Shareholder returns

FLGTIndustryMarket
7 Day-3.3%1.3%1.3%
30 Day28.7%-4.3%-4.1%
90 Day145.1%-0.7%8.4%
1 Year273.3%273.3%22.8%21.2%18.4%15.8%
3 Year714.6%714.6%23.8%18.5%38.2%29.0%
5 Yearn/a50.2%39.6%84.9%64.0%

Price Volatility Vs. Market

How volatile is Fulgent Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fulgent Genetics undervalued compared to its fair value and its price relative to the market?

313.77x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: FLGT ($38.94) is trading above our estimate of fair value ($8.84)

Significantly Below Fair Value: FLGT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: FLGT is poor value based on its PE Ratio (313.8x) compared to the US Healthcare industry average (22.2x).

PE vs Market: FLGT is poor value based on its PE Ratio (313.8x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

PEG Ratio: FLGT is poor value based on its PEG Ratio (4x)


Price to Book Ratio

PB vs Industry: FLGT is overvalued based on its PB Ratio (9.8x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is Fulgent Genetics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

79.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FLGT's forecast earnings growth (79% per year) is above the savings rate (2.2%).

Earnings vs Market: FLGT's earnings (79% per year) are forecast to grow faster than the US market (22.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: FLGT's revenue (33.3% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: FLGT's revenue (33.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FLGT's Return on Equity is forecast to be high in 3 years time (28.2%)


Next Steps

Past Performance

How has Fulgent Genetics performed over the past 5 years?

44.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FLGT has high quality earnings.

Growing Profit Margin: FLGT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: FLGT has become profitable over the past 5 years, growing earnings by 44.3% per year.

Accelerating Growth: FLGT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: FLGT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).


Return on Equity

High ROE: FLGT's Return on Equity (2.9%) is considered low.


Next Steps

Financial Health

How is Fulgent Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: FLGT's short term assets ($41.2M) exceed its short term liabilities ($6.5M).

Long Term Liabilities: FLGT's short term assets ($41.2M) exceed its long term liabilities ($2.4M).


Debt to Equity History and Analysis

Debt Level: FLGT is debt free.

Reducing Debt: FLGT has not had any debt for past 5 years.

Debt Coverage: FLGT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: FLGT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Fulgent Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FLGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FLGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FLGT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FLGT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FLGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Ming Hsieh (64 yo)

4.33yrs

Tenure

US$240,000

Compensation

Mr. Ming Hsieh is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and served as its Manager. Mr. Hsieh serves as President at Fulgent Therapeutics, ...


CEO Compensation Analysis

Compensation vs Market: Ming's total compensation ($USD240.00K) is below average for companies of similar size in the US market ($USD3.05M).

Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ming Hsieh
Chairman4.33yrsUS$240.00k35.71%
$ 307.5m
Paul Kim
Chief Financial Officer4.67yrsUS$823.48k0.99%
$ 8.5m
Han Gao
Chief Scientific Officer & Laboratory Director4yrsUS$329.70k8%
$ 68.9m
Jian Xie
Chief Operating Officerno datano datano data
Brandon Perthuis
Chief Commercial Officer0.50yrno datano data

4.2yrs

Average Tenure

53.5yo

Average Age

Experienced Management: FLGT's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ming Hsieh
Chairman4.33yrsUS$240.00k35.71%
$ 307.5m
John Bolger
Independent Director4yrsUS$77.20k0.0091%
$ 78.4k
Yun Yen
Independent Director4yrsUS$53.50k0%
$ 0
Linda Marsh
Independent Director1.08yrsUS$120.20k0%
$ 0

4.0yrs

Average Tenure

67.5yo

Average Age

Experienced Board: FLGT's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: FLGT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.6%.


Top Shareholders

Company Information

Fulgent Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fulgent Genetics, Inc.
  • Ticker: FLGT
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$861.144m
  • Shares outstanding: 22.11m
  • Website: https://www.fulgentgenetics.com

Number of Employees


Location

  • Fulgent Genetics, Inc.
  • 4978 Santa Anita Avenue
  • Suite 205
  • Temple City
  • California
  • 91780
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FLGTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 2016
7F0DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2016

Biography

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/29 00:26
End of Day Share Price2020/09/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.